You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,388,134


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,388,134 protect, and when does it expire?

Patent 9,388,134 protects ENTRESTO and is included in one NDA.

Protection for ENTRESTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-one patent family members in thirty-five countries.

Summary for Patent: 9,388,134
Title:Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Abstract: A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.
Inventor(s): Feng; Lili (Pine Brook, NJ), Godtfredsen; Sven Erik (Chatham, NJ), Sutton; Paul Allen (Parsippany, NJ), Prashad; Mahavir (Montville, NJ), Girgis; Michael J. (Montville, NJ), Hu; Bin (Green Brook, NJ), Liu; Yugang (Bridgewater, NJ), Blacklock; Thomas J. (East Hanover, NJ), Karpinski; Piotr Henryk (Lincoln Park, NJ)
Assignee: NOVARTIS, AG (Basel, CH)
Application Number:14/311,788
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,388,134
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,388,134

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp ENTRESTO sacubitril; valsartan TABLET;ORAL 207620-001 Jul 7, 2015 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Novartis Pharms Corp ENTRESTO sacubitril; valsartan TABLET;ORAL 207620-002 Jul 7, 2015 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Novartis Pharms Corp ENTRESTO sacubitril; valsartan TABLET;ORAL 207620-003 Jul 7, 2015 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,388,134

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 057882 ⤷  Try a Trial
Argentina 106613 ⤷  Try a Trial
Argentina 106614 ⤷  Try a Trial
Australia 2006311481 ⤷  Try a Trial
Brazil 122013025375 ⤷  Try a Trial
Brazil PI0605921 ⤷  Try a Trial
Canada 2590511 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.